A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Sponsor: Mayne Pharma International Pty Ltd
Listed as NCT03337490, this PHASE3 trial focuses on Head Lice and remains completed. Sponsored by Mayne Pharma International Pty Ltd, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayne Pharma International Pty Ltd
- bioRASI, LLC
For direct contact, visit the study record on ClinicalTrials.gov .